Genetic discrimination in life insurance: empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom

TLDR

Experiences with insurers are reported here. The study aimed to gather empirical evidence on genetic discrimination by UK life insurers and to assess societal responses to future genetic testing for polygenic conditions. A postal questionnaire survey of 7,000 support‑group members and 1,033 general‑public respondents collected data on experiences with insurers, the medical profession, employers, and social services. Among the support‑group sample, 33.4% reported problems applying for life insurance versus 5% in the general public, and 13% of low‑risk respondents reported unjustified genetic discrimination, indicating inconsistent insurer practices rather than systematic policy.

Abstract

<h3>Abstract</h3> <b>Objectives:</b> To gather empirical evidence on any discrimination based on genetic information shown by the insurance industry in the United Kingdom and to assess how society is likely to handle future genetic information from tests for polygenic multifactorial conditions. <b>Design:</b> Postal questionnaire survey. <b>Subjects:</b> Sample (n=7000) of members from seven British support groups for families with genetic disorders and a representative sample (n=1033) of the general public who answered questions on applying for life insurance as part of an omnibus survey. <b>Main outcome measures:</b> Subjects were asked about their experiences with insurers, the medical profession, employers, and social services. Experiences with insurers are reported here. <b>Results:</b> Altogether 33.4% of the study group had problems when applying for life insurance compared with 5% of applicants in the omnibus survey. Thirteen per cent of study respondents from subgroups who represented no adverse actuarial risk on genetic grounds reported that their treatment by insurers seemed to represent unjustified genetic discrimination. <b>Conclusions:</b> Life insurers may not be operating a consistent policy for assessing genetic information or acting in accord with the actuarial risks brought to them. The inconsistency suggests error rather than a corporate policy of discrimination based on genetic characteristics. Any future proposals for genetic testing for common or multifactorial disorders should be examined carefully.